Koers Aphria Inc Toronto S.E.
Aandelen
APH
CA03765K1049
Farmaceutische producten
Omzet 2024 * | 784 mln. 1,07 mld. 733 mln. | Omzet 2025 * | 865 mln. 1,18 mld. 809 mln. | Marktkapitalisatie | 1,38 mld. 1,88 mld. 1,29 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -211 mln. -288 mln. -197 mln. | Nettowinst (verlies) 2025 * | -86 mln. -118 mln. -80,43 mln. | EV/omzet 2024 * | 1,98 x |
Nettoschuld 2024 * | 178 mln. 243 mln. 166 mln. | Nettoschuld 2025 * | 108 mln. 148 mln. 101 mln. | EV/omzet 2025 * | 1,72 x |
K/w-verhouding 2024 * |
-5,95
x | K/w-verhouding 2025 * |
-12,5
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 98,67% |
Recentste transcriptie over Aphria Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Irwin Simon
CEO | Chief Executive Officer | 65 | 30-04-21 |
Carl Merton
DFI | Director of Finance/CFO | - | 30-04-21 |
Lloyd Brathwaite
CTO | Chief Tech/Sci/R&D Officer | - | 30-04-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Irwin Simon
CEO | Chief Executive Officer | 65 | 30-04-21 |
David Clanachan
BRD | Director/Board Member | 62 | 30-04-21 |
Walter Robb
BRD | Director/Board Member | 70 | 30-04-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,83% | 661 mld. | |
+27,00% | 566 mld. | |
-6,76% | 352 mld. | |
+20,34% | 332 mld. | |
+3,00% | 283 mld. | |
+13,09% | 231 mld. | |
+5,46% | 200 mld. | |
-9,61% | 195 mld. | |
-6,26% | 145 mld. |